Allist will strive to take its advantages in new drug discovery, increase R&D inputs, and intensify its efforts in accelerating exploring targeted drugs for cancer treatment.Meanwhile, Allist is working to expand its product pipeline in multiple ways including joint development and external introduction.
/>
Furmonertinib
(Core product)
RETinhibitor
KRAS G12C
inhibitor
KRAS G12D
inhibitor
SOS1
inhibitor
4th-generationEGFR
inhibitor
Treatment of Malignant Tumor
As an innovative pharmaceutical industrialization base invested by Shanghai Allist Pharmaceuticals, Jiangsu Allist Pharmaceuticals Co.,LTD was founded in Sept 2009 with a registered capital of 240 million RMB.Jiangsu Allist is located in No.666 Huashi Road, Qidong Economic Development Zone, Jiangsu Province, covering a total area of 73,337 square meter, 90Km away from Shanghai Pudong Airport, with convenient transportation and beautiful environment.
Scope of production license: Tablets (including antitumor drugs) and hard capsules (including antitumor drugs)
Focused on Cancer and other Maior Therapeutical Areas with Unmet Clinical Demands
ALLISTBD@meidatw.com
Two innovative drugs have been successfully developed and put into market, leading in China
Core technology platforms: Drug molecular design and discovery technology, drug design and optimization technology based on metabolism, with high success rate, good practicability and R&D efficiency;
Rich resources of clinical experts, especially in Lund Cancer;
Superior ability of translational medicine, highly recognized by clinical experts and peers of international top journals;
Professional and efficient clinical operation team and management;
With closed-loop development experience in the process of innovative drug development "R&D-Preclinical evalsuation-Clinical Transformation-Registration-Commercial Operation"
Wide and deep commercial operation network;
More than 350 talents for sales with extensive resources and rich experience;
>
>